Targeted Disease(s):
COPD
Purpose of Study:
This study is an exploratory, two-part, 12-week, Phase 2a study to evaluate the mechanism of action of Itepekimab (anti-IL-33-mAb) and its impact on airway inflammation in former and current smokers with COPD, aged 40 to 70 years.
Study Dates:
May 19, 2022 - March 20, 2025
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Funding Source:
Sanofi and Regeneron
Sponsors:
Sanofi and Regeneron
Contact:
Phone: 800-633-1610, option 6
tEmail: Contact-US@sanofi.com
ClinicalTrails.gov Identifier:
NCT05326412
